TY - JOUR
T1 - Association of dipeptidyl peptidase-4 inhibitor use and risk of pancreatic cancer in individuals with diabetes in Japan
AU - Kubota, Sodai
AU - Haraguchi, Takuya
AU - Kuwata, Hitoshi
AU - Seino, Yusuke
AU - Murotani, Kenta
AU - Tajima, Takumi
AU - Terashima, Gen
AU - Kaneko, Makiko
AU - Takahashi, Yoshihiro
AU - Takao, Ken
AU - Kato, Takehiro
AU - Shide, Kenichiro
AU - Imai, Saeko
AU - Suzuki, Atsushi
AU - Terauchi, Yasuo
AU - Yamada, Yuichiro
AU - Seino, Yutaka
AU - Yabe, Daisuke
N1 - Funding Information:
HK obtained grants from Ono, Taisho and Novo Nordisk. HK also obtained speaker fees from Sanofi and Taisho. AS received grants from MSD, EA, Ono, Taisho, Kowa, Takeda and Chugai. AS also obtained consulting or speaker fees from Asahi Kasei, Astellas, MSD, Kyowa‐Kirin, Amgen, Daiichi‐Sankyo, Tanabe‐Mitsubishi, Taisho, Chugai, Novo‐Nordisk, Pfizer and Eli‐Lilly. YasT obtained consulting or speaker fees for Daiichi Sankyo, AstraZeneca, Astellas, Boehringer Ingelheim, Bayer, Eli Lilly, Novo Nordisk, MSD, Mitsubishi, Ono, Tanabe, Sanofi, Sanwa Kagaku Kenkyusho, Shionogi and Teijin. YasT also obtained grants from AstraZeneca, Novartis, Boehringer Ingelheim, Astellas Pharma, Daiichi Sankyo, MSD, Novo Nordisk, Eli Lilly, Ono, Shionogi, Sanwa, Takeda, Sanofi and Sumitomo Dainippon. YY obtained grants from Ono, Daiichi Sankyo, Mitsubishi Tanabe, Sumitomo Dainippon, Takeda and Novo Nordisk. YY also obtained consulting or speaker fees from Mitsubishi Tanabe, MSD, Ono, Sumitomo Dainippon, Sanofi, Takeda, Daiichi Sankyo and Novo Nordisk. YutS obtained grants from Eli Lilly, Terumo, MSD, Taisho, Ono, Arklay, Novo Nordisk and Boehringer Ingelheim. YutS also obtained consulting or speaker fees from Glaxo‐Smith‐Kline, Johnson & Johnson, Eli Lilly, Taisho, Sanofi, Taisho, Novo Nordisk, Astellas, Takeda, Boehringer Ingelheim and BD. DY obtained grants from Novo Nordisk, Ono, Terumo, Taisho and Arklay. DY also obtained consulting or speaker fees from Boehringer Ingelheim, Astellas, MSD, Novo Nordisk, Sumitomo Dainippon, Ono, Eli Lilly and Takeda. The other authors declare no conflict of interest.
Funding Information:
The authors thank M Yato, Y Ogiso and M Nozu for secretarial assistance. KS, SI, AS, YT, YutY and DY are members of the Academic Affairs Committee, the Japan Association for Diabetes Education and Care, Tokyo 102‐0083, Japan. The study was supported by the Japan Association for Diabetes Education and Care. Raw data are available upon request.
Funding Information:
The authors thank M Yato, Y Ogiso and M Nozu for secretarial assistance. KS, SI, AS, YT, YutY and DY are members of the Academic Affairs Committee, the Japan Association for Diabetes Education and Care, Tokyo 102-0083, Japan. The study was supported by the Japan Association for Diabetes Education and Care. Raw data are available upon request.
Publisher Copyright:
© 2022 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd.
PY - 2023/1
Y1 - 2023/1
N2 - Aims/Introduction: This study was designed and carried out to investigate the association of dipeptidyl peptidase-4 inhibitor (DPP-4i) use with pancreatic cancer (PC) in individuals with diabetes in Japan. Materials and Methods: The JMDC Claims Database, which contains the medical and prescription information of Japanese employment-based health insurance programs, was used. The primary outcome was duration to the first occurrence of PC (International Classification of Diseases 10th Revision code C25), both all and hospitalized, from prescription of DPP-4is or other oral glucose-lowering agents (GLAs). Results: Individuals with diabetes who received DPP-4is (n = 61,430) or other oral GLAs (n = 83,304) were analyzed. Follow-up periods (median [interquartile range]) were 17 months (8–33) for DPP-4is and 14 months (7–28) for other oral GLAs. Kaplan–Meier curve analysis to determine the duration of first use of DPP4i or other oral GLA to diagnosis of PC disclosed no differences between the two groups in duration to all or hospitalized PC (log-rank test: all, P = 0.7140; hospitalized, P = 0.3446). Cox proportional hazards models showed that use of DPP-4is did not affect the PC risk adjusted for medications, age, sex and risk comorbidities (all, hazard ratio 1.1, 95% confidence interval 0.8–1.3, P = 0.6518; hospitalized, hazard ratio 1.1, 95% confidence interval 0.8–1.4, P = 0.6662). Similar results were obtained when individuals with ≥2 years oral GLA treatment and those with medical checkup data (e.g., smoking or drinking habit) available were analyzed. Conclusion: This database study shows that there is not a significant PC risk due to DPP-4i treatment in individuals with diabetes in Japan, but larger studies with longer follow up are required to confirm these findings.
AB - Aims/Introduction: This study was designed and carried out to investigate the association of dipeptidyl peptidase-4 inhibitor (DPP-4i) use with pancreatic cancer (PC) in individuals with diabetes in Japan. Materials and Methods: The JMDC Claims Database, which contains the medical and prescription information of Japanese employment-based health insurance programs, was used. The primary outcome was duration to the first occurrence of PC (International Classification of Diseases 10th Revision code C25), both all and hospitalized, from prescription of DPP-4is or other oral glucose-lowering agents (GLAs). Results: Individuals with diabetes who received DPP-4is (n = 61,430) or other oral GLAs (n = 83,304) were analyzed. Follow-up periods (median [interquartile range]) were 17 months (8–33) for DPP-4is and 14 months (7–28) for other oral GLAs. Kaplan–Meier curve analysis to determine the duration of first use of DPP4i or other oral GLA to diagnosis of PC disclosed no differences between the two groups in duration to all or hospitalized PC (log-rank test: all, P = 0.7140; hospitalized, P = 0.3446). Cox proportional hazards models showed that use of DPP-4is did not affect the PC risk adjusted for medications, age, sex and risk comorbidities (all, hazard ratio 1.1, 95% confidence interval 0.8–1.3, P = 0.6518; hospitalized, hazard ratio 1.1, 95% confidence interval 0.8–1.4, P = 0.6662). Similar results were obtained when individuals with ≥2 years oral GLA treatment and those with medical checkup data (e.g., smoking or drinking habit) available were analyzed. Conclusion: This database study shows that there is not a significant PC risk due to DPP-4i treatment in individuals with diabetes in Japan, but larger studies with longer follow up are required to confirm these findings.
UR - http://www.scopus.com/inward/record.url?scp=85140362015&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85140362015&partnerID=8YFLogxK
U2 - 10.1111/jdi.13921
DO - 10.1111/jdi.13921
M3 - Article
C2 - 36281720
AN - SCOPUS:85140362015
SN - 2040-1116
VL - 14
SP - 67
EP - 74
JO - Journal of Diabetes Investigation
JF - Journal of Diabetes Investigation
IS - 1
ER -